Last update Dec. 21, 2023

Flecainide Acetate

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Flecainide is a class Ic antiarrhythmic agent used to treat atrial fibrillation and paroxysmal supraventricular tachycardias.  It has also been tried to treat neuropathic pain. Oral or intravenous administration.

It is excreted in breast milk in a very small, clinically insignificant amount, much lower than the dose used in newborns and infants. (van der Zande 2023, McQuinn 1990, Wagner 1990)

In infants of mothers treated with flecainide no problems have been observed and its plasma levels were undetectable. (van der Zande 2023, Pizzoglio 2023)

American Academy of Pediatrics: medication generally compatible with breastfeeding. (AAP 2001)

Alternatives

We do not have alternatives for Flecainide Acetate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Flecainide Acetate in other languages or writings:

Group

Flecainide Acetate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Flecainide Acetate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 474 daltons
Protein Binding 40 - 50 %
VD 5 - 13.4 l/Kg
pKa 13.68 -
Tmax 3 - 4 hours
13 (7 - 22) hours
M/P ratio 2.6 - 3.7 -
Theoretical Dose 0.11 (0.02 - 0.23) mg/Kg/d
Relative Dose 3.3 (0.6 - 6.9) %
Ped.Relat.Dose 0.25 - 5.8 %

References

  1. van der Zande JA, Cornette JMJ, Roos-Hesselink JW, Flint RB. Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report. Int Breastfeed J. 2023 Apr 14;18(1):21. Consulted on Dec. 21, 2023 Abstract
  2. Pizzoglio V, Auffret M, Vial T, Gouraud A. Follow-up of flecainide breastfed infants. Fundam Clin Pharmacol 2023;37:143-4. Supplement: Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France. Poster 092 Consulted on Dec. 21, 2023 Abstract Full text (link to original source)
  3. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  4. Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990 Abstract
  5. McQuinn RL, Pisani A, Wafa S, Chang SF, Miller AM, Frappell JM, Chamberlain GV, Camm AJ. Flecainide excretion in human breast milk. Clin Pharmacol Ther. 1990 Abstract

Total visits

9,942

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM